Anthony Doyle - Net Worth and Insider Trading

Anthony Doyle Net Worth

The estimated net worth of Anthony Doyle is at least $2 Million dollars as of 2024-06-08. Anthony Doyle is the CFO of BioCryst Pharmaceuticals Inc and owns about 266,744 shares of BioCryst Pharmaceuticals Inc (BCRX) stock worth over $2 Million. Details can be seen in Anthony Doyle's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Anthony Doyle has not made any transactions after 2024-05-14 and currently still holds the listed stock(s).

Transaction Summary of Anthony Doyle

To

Anthony Doyle Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Anthony Doyle owns 1 companies in total, including BioCryst Pharmaceuticals Inc (BCRX) .

Click here to see the complete history of Anthony Doyle’s form 4 insider trades.

Insider Ownership Summary of Anthony Doyle

Ticker Comapny Transaction Date Type of Owner
BCRX BioCryst Pharmaceuticals Inc 2024-05-14 Chief Financial Officer

Anthony Doyle Latest Holdings Summary

Anthony Doyle currently owns a total of 1 stock. Anthony Doyle owns 266,744 shares of BioCryst Pharmaceuticals Inc (BCRX) as of May 14, 2024, with a value of $2 Million.

Latest Holdings of Anthony Doyle

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BCRX BioCryst Pharmaceuticals Inc 2024-05-14 266,744 6.31 1,683,155

Holding Weightings of Anthony Doyle


Anthony Doyle Form 4 Trading Tracker

According to the SEC Form 4 filings, Anthony Doyle has made a total of 4 transactions in BioCryst Pharmaceuticals Inc (BCRX) over the past 5 years, including 3 buys and 1 sells. The most-recent trade in BioCryst Pharmaceuticals Inc is the acquisition of 36,300 shares on May 14, 2024, which cost Anthony Doyle around $202,191.

Insider Trading History of Anthony Doyle

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Anthony Doyle Trading Performance

GuruFocus tracks the stock performance after each of Anthony Doyle's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Anthony Doyle is 21.29%. GuruFocus also compares Anthony Doyle's trading performance to market benchmark return within the same time period. The performance of stocks bought by Anthony Doyle within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Anthony Doyle's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Anthony Doyle

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
2 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 8.48 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 7.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Anthony Doyle Ownership Network

Ownership Network List of Anthony Doyle

No Data

Ownership Network Relation of Anthony Doyle

Insider Network Chart

Anthony Doyle Owned Company Details

What does BioCryst Pharmaceuticals Inc do?

Who are the key executives at BioCryst Pharmaceuticals Inc?

Anthony Doyle is the Chief Financial Officer of BioCryst Pharmaceuticals Inc. Other key executives at BioCryst Pharmaceuticals Inc include Vice President and CCO Charles K Gayer , VP & General Counsel & Corp Sec Alane P Barnes , and director & CEO Jon P Stonehouse .

BioCryst Pharmaceuticals Inc (BCRX) Insider Trades Summary

Over the past 18 months, Anthony Doyle made 2 insider transaction in BioCryst Pharmaceuticals Inc (BCRX) with a net purchase of 30,600. Other recent insider transactions involving BioCryst Pharmaceuticals Inc (BCRX) include a net sale of 84,100 shares made by Jon P Stonehouse , a net purchase of 19,875 shares made by Helen M. Thackray , and a net purchase of 23,900 shares made by Charles K Gayer .

In summary, during the past 3 months, insiders sold 0 shares of BioCryst Pharmaceuticals Inc (BCRX) in total and bought 183,601 shares, with a net purchase of 183,601 shares. During the past 18 months, 157,511 shares of BioCryst Pharmaceuticals Inc (BCRX) were sold and 183,601 shares were bought by its insiders, resulting in a net purchase of 26,090 shares.

BioCryst Pharmaceuticals Inc (BCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

BioCryst Pharmaceuticals Inc Insider Transactions

No Available Data

Anthony Doyle Mailing Address

Above is the net worth, insider trading, and ownership report for Anthony Doyle. You might contact Anthony Doyle via mailing address: 4505 Emperor Blvd., Suite 200, Durham Nc 27703.

Discussions on Anthony Doyle

No discussions yet.